Xeljanz (ZEL-jans, tofacitinib), a new ORAL treatment for moderate to severe rheumatoid arthritis in adults

September 2014

You'll see Xeljanz (ZEL-jans, tofacitinib), a new ORAL treatment for moderate to severe rheumatoid arthritis in adults.

It's the first Janus kinase (JAK) inhibitor for RA. Janus kinase enzymes are linked to inflammation in joints and other tissues.

Xeljanz is approved to be added to methotrexate if needed...or used alone in patients who can't tolerate methotrexate.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Influenza more opportunities for pharmacists to give flu vaccines this fall
Dyslipidemia higher doses of statins increasing the risk of diabetes
Dyslipidemia Patients will ask if they should stop niacin (Niaspan, etc)
Smoking Cessation About one in six Canadian adults still use tobacco, and your intervention can significantly improve their chances of quitting
Vaccines More of your asthma patients will be candidates for pneumococcal vaccination
Depression Strategies for augmenting antidepressants
Rheumatoid Arthritis Xeljanz (ZEL-jans, tofacitinib), a new ORAL treatment for moderate to severe rheumatoid arthritis in adults
Oral Health if electric toothbrushes (Oral-B Professional Care, Sonicare, Spinbrush, etc) are worth the extra cost
Diuretics how to manage hypokalemia in patients on diuretics (hydrochlorothiazide, furosemide, etc)
ADHD whether ADHD stimulants increase cardiovascular risk in children and adolescents
Med Administration how to give meds via enteral tubes